CeriBell, Inc. Common Stock Canaccord Genuity's 46th Annual Growth Conference

Thanks, Bill. CeriBell is a publicly traded medical technology company that makes brainwave monitoring, EEG, much quicker. We've overlaid that with a number of AI-powered algorithms to help detect serious neurological conditions that affect people in the acute care setting, which is the emergency room and the ICU. EEG, as a technology, has been around for quite a while, over a century, and it was designed specifically for diagnosis of patients with epilepsy in the outpatient setting. It's now been applied to the inpatient setting, the ICU and the ED, where the most important thing for a patient to have a good outcome is the speed of diagnosis and treatment, and it's not designed for speed.

It has a number of inherent bottlenecks in the technology, including having large equipment that needs to be wheeled around the hospital and relying on specially trained EEG technicians and neurologists, which are in short supply and not readily available. We have changed that equation with our technology. We have developed a technology that's very easy to be set up. It can be set up in about 5 minutes by any trained medical professional, most often nurses. Then we've overlaid that with, as I mentioned, detection algorithms, which allow the bedside clinicians to understand what's going on with the patient in real time. Technology's very well studied. We've got over 50 publications, over 150 publications and abstracts. The data strongly supports that we provide better medicine. The clinicians feel better about their treatment decisions. They overuse medication less. We have a lower length of stay.

We reduce transfers, and that's evident in the fact that we're now in 712 hospitals in the U.S. and growing. That represents the first horizon of our vision, which is specifically targeting seizure. We want to become the standard of care for seizure detection in the acute care setting. As we moved into 2026, we're now pursuing the second phase of our vision in parallel, which is to develop a comprehensive brain monitor and become a vital sign for the acute care setting. We've done that by overlaying new disease state detection algorithms onto the same platform. Also announced in our earnings call Monday, we're rolling out a new hardware platform, which works for all of seizure, delirium, and then eventually stroke when we roll that out. Delirium is a very prevalent condition affecting the same patient population, as well as additional patients in the ICU.

We received clearance for that late last year, are currently undergoing a pilot with a small number of studies and announced an intention to launch that product later this year. We received, about two weeks ago, favorable reimbursement from CMS for a new technology add-on payment, which adds over $2,000 per eligible patient. In stroke, we've received a FDA breakthrough designation on that technology. It's still in development, but we're making steady progress. We're still in the early innings of penetration within our core market. We've got about a $2 billion U.S. TAM for the adult seizure detection product, and we're roughly 4% into that and growing.

We are continually growing our TAM, first adding younger patients early this year with neonates and pediatrics, and now delirium, bringing our U.S. TAM up to over $3.5 billion, and that doesn't include future indications as well as OUS. I will turn it over to Bill.

We don't, no. Okay. No, we're going to roll those out.

I'm happy to talk through them, though, yeah.

Yeah, let me first clarify the commercial model. We've got basically two distinct sales orgs. We've got the territory manager, the account acquisition arm, and they're focused on acquiring new customers. That's, I think, what you referred to on the acceleration side. Then separate from that, we've got the account management function, which is clinical account managers, and they singularly focus on utilization. As far as the ramp for the territory managers go, we have about six or seven years of history showing with pretty high confidence how these folks ramp. It takes about a year for a territory manager to launch their first account, and the math there is roughly three months to bring on, train, onboard the rep. Roughly six months from first approach to purchase order. Of course, that varies. Then from purchase order to launch, roughly three months.

It takes about a year for a rep to become productive, and then we see increasing productivity over the second year, and then they reach max productivity, which is not a cap, it's a max of the rate of adds by year 2. So, we expanded our territory manager post-IPO from roughly 35 to 55, and it took us about a year to do that. So if you think about that one year hiring cycle as kind of like a ship moving forward. The front half of the ship has now crossed into the one year, some productivity category. The back half is not there yet. As we move further into the year, more of them hit the one year, and then the first of them hit the two-year mark.